TDMS Study 88034-06 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
OZONE
NTP Experiment-Test: 88034-06 Report: PEIRPT05
Study Type: CHRONIC 30-MONTH Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
Facility: Battelle Northwest
Chemical CAS #: 10028-15-6
Lock Date: 03/09/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund Sacrifice 34 25 33
Natural Death 7 13 7
Survivors
Terminal Sacrifice 9 12 10
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (43) (38) (44)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Intestine Large, Cecum (45) (43) (47)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (45) (41) (46)
Peyer's Patch, Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (44) (42) (47)
Intestine Small, Ileum (45) (43) (46)
Carcinoma 1 (2%)
Liver (49) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Hepatocellular Carcinoma 15 (31%) 15 (30%) 6 (12%)
Hepatocellular Carcinoma, Multiple 4 (8%) 3 (6%) 2 (4%)
Hepatocellular Adenoma 11 (22%) 12 (24%) 9 (18%)
Hepatocellular Adenoma, Multiple 2 (4%) 4 (8%) 4 (8%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 3 (6%) 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mesentery (13) (5) (10)
Hemangiosarcoma 1 (20%)
Histiocytic Sarcoma 1 (10%)
Sarcoma, Metastatic, Skin 1 (8%)
Pancreas (48) (48) (49)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (50) (48) (49)
Sarcoma 1 (2%)
Stomach, Forestomach (48) (50) (49)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (48) (49) (48)
Histiocytic Sarcoma 1 (2%)
Page 2
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Metastatic, Skin 1 (2%)
Tooth (1)
Adamantinoma Malignant 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (48) (49) (50)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (48) (49) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 2 (4%) 2 (4%) 1 (2%)
Islets, Pancreatic (47) (47) (48)
Adenoma 1 (2%)
Pituitary Gland (48) (48) (49)
Pars Distalis, Adenoma 19 (40%) 11 (23%) 12 (24%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 3 (6%)
Thyroid Gland (49) (49) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
Follicular Cell, Adenoma, Multiple 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (48) (50)
Cystadenoma 4 (8%) 2 (4%) 2 (4%)
Granulosa Cell Tumor Benign 1 (2%)
Hemangioma 1 (2%) 2 (4%)
Histiocytic Sarcoma 2 (4%) 2 (4%)
Luteoma 1 (2%) 1 (2%) 1 (2%)
Uterus (49) (50) (50)
Adenoma 1 (2%)
Fibroma 1 (2%)
Page 3
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Hemangioma 1 (2%) 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 3 (6%) 1 (2%)
Leiomyoma 1 (2%)
Polyp Stromal 3 (6%) 2 (4%) 6 (12%)
Polyp Stromal, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (50)
Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Lymph Node (15) (6) (9)
Iliac, Histiocytic Sarcoma 2 (13%)
Pancreatic, Histiocytic Sarcoma 1 (7%)
Renal, Histiocytic Sarcoma 1 (7%) 1 (11%)
Lymph Node, Bronchial (36) (32) (33)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%) 1 (3%)
Lymph Node, Mandibular (38) (40) (41)
Histiocytic Sarcoma 2 (5%)
Lymph Node, Mesenteric (45) (48) (44)
Histiocytic Sarcoma 3 (7%) 1 (2%)
Lymph Node, Mediastinal (43) (36) (38)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 2 (5%) 1 (3%)
Spleen (49) (50) (50)
Hemangiosarcoma 2 (4%) 3 (6%) 3 (6%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Thymus (35) (35) (33)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50)
Adenoma 1 (2%)
Carcinoma 3 (6%) 2 (4%) 2 (4%)
Carcinoma, Multiple 1 (2%)
Skin (50) (50) (50)
Schwannoma Malignant 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 2 (4%)
Page 4
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 2 (4%) 5 (10%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Hemangiosarcoma 1 (2%)
Osteosarcoma 2 (4%) 1 (2%)
Skeletal Muscle (2)
Histiocytic Sarcoma 1 (50%)
Rhabdomyosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (49) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (50)
Adamantinoma Malignant, Metastatic, Tooth 1 (2%)
Alveolar/Bronchiolar Adenoma 3 (6%) 3 (6%) 10 (20%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 5 (10%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 5 (10%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 2 (4%)
Mediastinum, Hemangiosarcoma 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Mediastinum, Osteosarcoma, Metastatic, Bone 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%)
Nose (50) (49) (50)
Adenoma 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Page 5
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (5) (3)
Adenoma 4 (80%) 4 (80%) 2 (67%)
Carcinoma 1 (20%) 1 (20%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Urinary Bladder (47) (48) (46)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 4 (8%) 3 (6%)
Lymphoma Malignant 13 (26%) 12 (24%) 13 (26%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 49 47
Total Primary Neoplasms 115 100 105
Total Animals with Benign Neoplasms 39 32 35
Total Benign Neoplasms 62 43 59
Total Animals with Malignant Neoplasms 39 39 34
Total Malignant Neoplasms 53 57 46
Total Animals with Metastatic Neoplasms 8 10 2
Total Metastatic Neoplasm 17 17 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Natural Death 10 9 15
Moribund Sacrifice 26 30 23
Survivors
Terminal Sacrifice 14 11 12
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (44) (45) (40)
Carcinoma 1 (3%)
Intestine Small, Duodenum (44) (45) (38)
Intestine Small, Jejunum (43) (44) (41)
Carcinoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Intestine Small, Ileum (44) (45) (40)
Liver (49) (50) (50)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 7 (14%) 14 (28%) 14 (28%)
Hepatocellular Carcinoma, Multiple 13 (27%) 3 (6%) 7 (14%)
Hepatocellular Adenoma 6 (12%) 12 (24%) 11 (22%)
Hepatocellular Adenoma, Multiple 7 (14%) 6 (12%) 1 (2%)
Hepatocholangiocarcinoma 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Seminal Vesicle 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (3) (3) (4)
Hemangioma 1 (33%)
Hemangiosarcoma 1 (33%)
Sarcoma, Metastatic, Seminal Vesicle 1 (33%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (33%)
Oral Mucosa (1)
Pharyngeal, Squamous Cell Carcinoma 1 (100%)
Pancreas (49) (49) (49)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Page 8
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Salivary Glands (49) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma 1 (2%)
Stomach, Forestomach (49) (49) (50)
Sarcoma, Metastatic, Seminal Vesicle 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 2 (4%) 1 (2%)
Stomach, Glandular (49) (47) (48)
Sarcoma, Metastatic, Seminal Vesicle 1 (2%)
Tooth (1)
Odontoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (47) (49) (49)
Adenoma 2 (4%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Seminal Vesicle 1 (2%)
Adrenal Medulla (48) (48) (49)
Pheochromocytoma Benign 1 (2%)
Sarcoma, Metastatic, Seminal Vesicle 1 (2%)
Islets, Pancreatic (49) (49) (49)
Adenoma 1 (2%)
Pituitary Gland (47) (49) (48)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 2 (4%)
Thyroid Gland (49) (48) (50)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Preputial Gland (49) (49) (49)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Prostate (48) (47) (47)
Seminal Vesicle (48) (49) (49)
Sarcoma 1 (2%)
Testes (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Interstitial Cell, Adenoma 2 (4%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Femoral, Mast Cell Tumor NOS 1 (2%)
Lymph Node (2) (3) (7)
Lymph Node, Bronchial (26) (27) (32)
Sarcoma, Metastatic, Uncertain Primary Site 1 (3%)
Lymph Node, Mandibular (34) (31) (32)
Lymph Node, Mesenteric (48) (46) (44)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Lymph Node, Mediastinal (37) (39) (43)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Spleen (49) (49) (50)
Hemangiosarcoma 1 (2%) 3 (6%) 4 (8%)
Mast Cell Tumor NOS 1 (2%)
Thymus (29) (26) (25)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (50)
Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 2 (4%)
Subcutaneous Tissue, Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (2) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Sarcoma, Metastatic, Seminal Vesicle 1 (50%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (49) (50)
Choristoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (49) (50)
Alveolar/Bronchiolar Adenoma 7 (14%) 8 (16%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 10 (20%) 14 (28%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 5 (10%) 4 (8%)
Carcinoma, Metastatic, Harderian Gland 2 (4%) 1 (2%)
Carcinoma, Metastatic, Salivary Glands 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 4 (8%) 7 (14%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 1 (2%)
Mediastinum, Hemangioma 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Nose (49) (48) (49)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (7) (8) (5)
Adenoma 6 (86%) 5 (63%) 4 (80%)
Carcinoma 2 (25%) 1 (20%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Urinary Bladder (47) (49) (48)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 2 (4%) 3 (6%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 50 42
Total Primary Neoplasms 78 90 88
Total Animals with Benign Neoplasms 28 32 23
Total Benign Neoplasms 37 37 31
Total Animals with Malignant Neoplasms 30 41 40
Total Malignant Neoplasms 40 53 55
Total Animals with Metastatic Neoplasms 11 7 12
Total Metastatic Neoplasm 25 7 20
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 1
Total Uncertain Neoplasms 1 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------